HERCESSI™ becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
11/14/2025 Motion to extend the time to file a response from December 1, 2025 to January 15, 2026, submitted to The Clerk. 11/14/2025 Response of Express Scripts, Inc., et al. to motion submitted.
CHARLESTON, W.Va. (WBOY) — West Virginia’s attorney general said in a press release Monday that “opioid manufacturers have been held accountable, now it’s time for others who illegally profited behind ...
The room we are in is locked. It is windowless and lit from above by a fluorescent bulb. In the hallway outside—two stories beneath the city of London—attendants in dark suits patrol silently, giving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback